Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 3:45 AM ET

Life Sciences Tools and Services

Company Overview of Antitope Limited

Company Overview

Antitope Limited, a biotechnology research company, develops non-immunogenic protein therapeutics. The company provides immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. It offers EpiScreen, an ex vivo human T cell assay technology for predicting the immunogenicity of biologics or for identifying T cell epitopes within the sequences of biologics; Composite Human Antibody technology for generating humanized antibodies devoid of human T cell epitopes; and Composite Protein technology for generating therapeutic proteins devoid of human T cell epitopes. The company also provides pANT Vector System, an expression system to enhance expressio...

Babraham Research Campus

Babraham

Cambridge,  CB22 3AT

United Kingdom

Founded in 2004

Phone:

44 1223 903496

Fax:

44 1223 496191

Key Executives for Antitope Limited

Chief Executive Officer and Director
Age: 47
Co-Founder, Chief Scientific Officer and Director
Age: 44
Chief Financial Officer
Age: 50
Vice President of Business Development
Research Director
Compensation as of Fiscal Year 2015.

Antitope Limited Key Developments

Antitope Limited Enters into an Agreement with Apitope

Antitope Limited has entered into an agreement with Apitope Under the agreement, Antitope will investigate and measure the immunological status of haemophilia A patients after treatment. Apitope's patented discovery platform enables selection of potential disease-modifying peptide therapies for the autoimmune disease of interest. It has a pipeline of compounds in development including ATX-F8-117, which has been designed to induce immune tolerance to blood coagulation factor VIII in haemophilia A patients. Haemophilia A is caused by a deficiency in blood coagulation factor VIII and is treated with replacement factor VIII protein. About 30% of haemophilia A patients develop neutralising antibodies to factor VIII which inhibits its activity and thus renders treatment less effective. Such patients are at risk of serious and life-threatening bleeding.

Antitope Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015

Antitope Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Antitope, INSERM and Baylor Institute to Collaborate to Produce Manufacturing Cell Lines for Two Novel Vaccines for HIV

Antitope Limited announced that it has extended its relationship with INSERM, ANRS and the Baylor Institute for Immunology Research. INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens. Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.

Similar Private Companies By Industry

Company Name Region
Plant Bioscience Limited Europe
Pleiad Group Ltd. Europe
Molecular Profiles Ltd. Europe
Polaris Biopharma Consulting Ltd Europe
ChemOvation Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Antitope Limited, please visit www.antitope.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.